SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-019351
Filing Date
2024-02-23
Accepted
2024-02-23 16:05:29
Documents
18
Period of Report
2024-02-22

Document Format Files

Seq Description Document Type Size
1 PRE 14A mcrb-20240222.htm   iXBRL PRE 14A 1306550
2 GRAPHIC img115649641_0.jpg GRAPHIC 11749
3 GRAPHIC img115649641_1.jpg GRAPHIC 166528
4 GRAPHIC img115649641_2.jpg GRAPHIC 170485
5 GRAPHIC img115649641_3.jpg GRAPHIC 491444
6 GRAPHIC img115649641_4.jpg GRAPHIC 240498
  Complete submission text file 0000950170-24-019351.txt   4396265

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20240222.xsd EX-101.SCH 40502
19 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20240222_htm.xml XML 132205
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37465 | Film No.: 24671118
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)